UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.

drug manufacturing
World’s Largest Cell and Gene Therapy Plant Opens
World’s Largest Cell and Gene Therapy Plant Opens
Catherine Offord | Apr 11, 2018
Lonza will employ more than 200 full-time staff to work at the Texas-based facility, the company says.
Puerto Rico’s Hurricane Damage May Mean Drug Shortages
Puerto Rico’s Hurricane Damage May Mean Drug Shortages
Ashley P. Taylor | Oct 11, 2017
Three weeks after Hurricane Maria hit the island, pharmaceutical plants are not back up to speed.
Daraprim Discounts Offered
Daraprim Discounts Offered
Karen Zusi | Nov 26, 2015
Turing Pharmaceuticals will soon offer discounts to hospitals for its toxoplasmosis-fighting drug, the company announced, but some say the proposed price reductions are not enough.
Novartis Linked to Retracted Papers?
Novartis Linked to Retracted Papers?
Dan Cossins | Apr 2, 2013
A Japanese newspaper claims that the pharma giant funded flawed research that revealed extra health benefits for one of its top-selling drugs.
Regulations for Biosimilars
Lisa A. Haile and Kimberly K. Egan | Jun 1, 2012
As biologic drug patents begin to expire, generic versions will hit the market—but how will they be regulated?
Bogus Isomer Vendors Identified
Sabrina Richards | May 25, 2012
Pharma company publishes a list of 17 companies known to have sold the incorrect isomer of the kinase inhibitor bosutinib.
Mismarketed Chemical Causes Concern
Sabrina Richards | May 13, 2012
An incorrect isomer of the kinase inhibitor bosutinib is circulating in the biomedical research community, potentially throwing doubt on study results.
A Bill to Expedite Drug Production
Jef Akst | Feb 2, 2012
Legislation proposes speeding certain drug applications submitted to the US Food and Drug Administration.